Trimmed population | Stratified-matched population | |||||||
---|---|---|---|---|---|---|---|---|
Rituximab | Anti-TNF agent | Rituximab | Anti-TNF | |||||
(n = 265) | (n = 737) | (n = 205) | (n = 205) | |||||
Patients, number | LDA or remission | Patients, number | LDA or remission | Patients, number | LDA or remission | Patients, number | LDA or remission | |
Overall, n (%)* | 265 | 91 (34.3) | 737 | 248 (33.7) | 205 | 75 (36.6) | 205 | 59 (28.8) |
Remained on drug | 165 | 71 (43.0) | 379 | 196 (51.7) | 127 | 59 (46.5) | 94 | 45 (47.9) |
Not retreated with rituximab or discontinued anti-TNF | 57 | 20 (35.1) | 141 | 52 (36.9) | 47 | 16 (34.0) | 40 | 14 (35.0) |
Switched | 43 | N/A | 217 | N/A | 31 | N/A | 71 | N/A |